Life under FDAAA: What the FDA wants in medguide assessments
This article was originally published in Scrip
Executive Summary
The US FDA has a message for industry: it does not yet like what it sees in sponsors' proposals for assessing the effectiveness of medication guides under new risk evaluation and mitigation strategies (REMS).